Have a feature idea you'd love to see implemented?
Let us know!
OVID Ovid Therapeutics Inc
Price (delayed)
$0.9859
Market cap
$70.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.47
Enterprise value
$69.11M
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these
Highlights
OVID's revenue has surged by 113% year-on-year and by 11% since the previous quarter
The gross profit has soared by 113% YoY and by 11% from the previous quarter
The net income has grown by 33% YoY but it has contracted by 9% from the previous quarter
The EPS is up by 32% YoY but it is down by 9% QoQ
OVID's quick ratio is down by 46% YoY
OVID's equity is down by 25% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of OVID
Market
Valuations
Earnings
Shares outstanding
71.01M
Market cap
$70.01M
Enterprise value
$69.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.92
Price to sales (P/S)
110.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
109.42
Revenue
$631,563
Gross profit
$631,563
Net income
-$32.5M
EBIT
-$32.5M
EBITDA
-$30.83M
Free cash flow
-$57.92M
Per share
Balance sheet
Liquidity
EPS
-$0.47
EPS diluted
-$0.47
Free cash flow per share
-$0.82
Book value per share
$1.07
Revenue per share
$0.01
TBVPS
$1.45
Total assets
$102.65M
Total liabilities
$26.36M
Debt
$16.05M
Equity
$76.29M
Working capital
$54.2M
Debt to equity
0.21
Current ratio
5.66
Quick ratio
5.56
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
-4,881.8%
Gross margin
100%
Net margin
-5,146.1%
Operating margin
-10,980.4%
Return on assets
-26.2%
Return on equity
-39.2%
Return on invested capital
-28%
Return on capital employed
-35.7%
Return on sales
-5,146.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OVID stock price
How has the Ovid Therapeutics stock price performed over time
Intraday
2.03%
1 week
-3.34%
1 month
-9.55%
1 year
-70.92%
YTD
-69.38%
QTD
-16.45%
Financial performance
How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$631,563
Gross profit
$631,563
Operating income
-$69.35M
Net income
-$32.5M
Gross margin
100%
Net margin
-5,146.1%
OVID's revenue has surged by 113% year-on-year and by 11% since the previous quarter
The gross profit has soared by 113% YoY and by 11% from the previous quarter
Ovid Therapeutics's net margin has surged by 69% YoY
The operating margin has grown by 39% YoY and by 9% from the previous quarter
Growth
What is Ovid Therapeutics's growth rate over time
Valuation
What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
0.92
P/S
110.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
109.42
The EPS is up by 32% YoY but it is down by 9% QoQ
OVID's price to book (P/B) is 64% less than its 5-year quarterly average of 2.5 and 50% less than its last 4 quarters average of 1.8
OVID's equity is down by 25% YoY and by 14% from the previous quarter
OVID's revenue has surged by 113% year-on-year and by 11% since the previous quarter
OVID's price to sales (P/S) is 66% less than its last 4 quarters average of 316.1 and 65% less than its 5-year quarterly average of 312.8
Efficiency
How efficient is Ovid Therapeutics business performance
The ROS has soared by 69% YoY
OVID's ROIC is up by 50% YoY but it is down by 5% QoQ
The return on assets has increased by 24% year-on-year but it has declined by 14% since the previous quarter
Ovid Therapeutics's ROE has decreased by 17% from the previous quarter but it has increased by 6% YoY
Dividends
What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OVID.
Financial health
How did Ovid Therapeutics financials performed over time
The company's current ratio fell by 47% YoY
OVID's quick ratio is down by 46% YoY
Ovid Therapeutics's debt is 79% lower than its equity
Ovid Therapeutics's debt to equity has increased by 31% YoY and by 17% from the previous quarter
OVID's equity is down by 25% YoY and by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.